AMCP Annual

In this interview, Luis Ortiz, M.D., explains the current and emerging therapies for narcolepsy type 1 treatment.

Evernorth’s Nicole A. Caffiero said specialty drugs dominate the pipeline, FDA approvals and the expenditures on pharmaceuticals during a keynote presentation at the AMCP annual meeting.

A CVS Caremark formulary change in May 2025 led to a short increase in patients switching GLP-1 drugs before prescribing trends leveled off, according to Truveta data presented at AMCP.

In this interview, Luis Ortiz, M.D., explains how burdensome a narcolepsy diagnosis can be for a patient and why listening to their experiences helps shape new guidelines and treatments.

Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, explains how managed care organizations can support patients at risk of HIV.

The Maximum Fair Price (MFP), established by the Inflation Reduction Act, and the Most Favored Nation policy are reshaping how drugs are priced, paid for, and accessed.

Brian MacDonald, Pharm.D., of Prime Therapeutics discusses the low utilization of the gene therapies for hemophilia. Pfizer and BioMarin have pulled their FDA-approved hemophilia gene therapies from the market, citing low demand.

Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand.

As CAR-T therapy expands into earlier stages of treatment and new care settings, payers are weighing access, cost savings and utilization management strategies.

Data from an automated refill reminder program identified key patient behaviors and characteristics that strongly predict medication nonadherence, which could enable more targeted interventions by health plans in the future.

The anti-obesity market is now the fourth largest and is expected to grow. The pipeline contains 190 obesity-related products, IQVIA’s Scott Biggs said.

In this interview, Luis Ortiz, M.D., explains how narcolepsy type 1 is now diagnosed and how it differs from type 2.

Navitus Health Solutions saw both overall savings and reduced patient costs from the switch to the adalimumab biosimilars. Vanderbilt Health, however, experienced increased adverse events after the biosimilar conversation and further switching to other biosimilars or therapies.

Evaluating the costs and outcomes of alternative funding programs requires balancing financial objectives with patient considerations.

At the AMCP Annual Meeting, experts from Prime Therapeutics said education, policy alignment and collaboration can help improve access to precision testing while managing costs.

Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, explains where managed healthcare organizations should look if they want to improve PrEP access and align with public health goals.

In this video interview, Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, provides an overview of the HIV preventative medicine landscape.

In this first part of a video interview series, Abby Kim, Pharm.D., of Prime Therapeutics shows how advances such as precision medicine and CAR T therapy are improving outcomes while requiring managed care leaders to rethink value through a long-term lens of cost, toxicity and patient access.

A talk by presidential historian Jon Meacham kicked off the official beginning of the meeting at the Music City Center in Nashville, Tennessee.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, and Doug Long, MBA, vice president of industry relations at IQVIA.

At the 2025 AMCP annual meeting in Houston from March 31 to April 3, John M. O'Brien, Pharm.D., MPH, president and CEO of the National Pharmaceutical Council (NPC), shared concerns and potential reforms in a conversation with Managed Healthcare Executive.

Here’s what you missed this week on Managed Healthcare Executive.

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting factors.

Doug Long, BA, MBA, vice president of Industry Relations at IQVIA, shares what's happening in the growing GLP-1 and biosimilars space. Long was a presenter at the annual AMCP 2025 meeting in Houston, where he discussed these topics and more earlier this week.

Originally developed to treat Type 2 diabetes, glucagon-like peptide 1 (GLP-1s) are now being studied to explore their effects on various other conditions, such as sleep apnea, substance use disorder and Alzheimer’s disease, according to panelists participating in a keynote session of the Academy of Managed Care Pharmacy annual meeting today in Houston.

Maria Lowe, Ph.D., associate vice president of Pharmaceutical Intelligence at Institute for Clinical and Economic Review (ICER) addresses the possible gene therapies that we could see reach the market this year.